Evidence map›Paper›PMID 40493277›Full record

ArticleMolecular biology reports2025

Precore G1896A mutation of hepatitis B virus in patients with chronic hepatitis B, hepatic cirrhosis, and hepatocellular carcinoma in Burkina Faso.

Hodabalou Essoyomèwè Eugène Languie, Pegdwendé Abel Sorgho, Rogomenoma Alice Ouedraogo, Albert Théophane Yonli, Abdoul Karim Ouattara, Sidnooma Véronique Zongo, Théodora Mahoukèdè Zohoncon, Jacques Simpore

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hodabalou Essoyomèwè Eugène LanguieUniversity of Joseph KI-ZERBO, P.O. Box 7021 Ouagadougou 03, Ouagadougou, Burkina Faso.
Pegdwendé Abel SorghoUniversity of Joseph KI-ZERBO, P.O. Box 7021 Ouagadougou 03, Ouagadougou, Burkina Faso.
Rogomenoma Alice OuedraogoUniversity of Joseph KI-ZERBO, P.O. Box 7021 Ouagadougou 03, Ouagadougou, Burkina Faso.
Albert Théophane YonliUniversity of Joseph KI-ZERBO, P.O. Box 7021 Ouagadougou 03, Ouagadougou, Burkina Faso.
Abdoul Karim OuattaraUniversity of Joseph KI-ZERBO, P.O. Box 7021 Ouagadougou 03, Ouagadougou, Burkina Faso.
Sidnooma Véronique ZongoUniversity of Joseph KI-ZERBO, P.O. Box 7021 Ouagadougou 03, Ouagadougou, Burkina Faso.
Théodora Mahoukèdè ZohonconUniversity of Joseph KI-ZERBO, P.O. Box 7021 Ouagadougou 03, Ouagadougou, Burkina Faso. zohoncont1@yahoo.fr.
Jacques SimporeUniversity of Joseph KI-ZERBO, P.O. Box 7021 Ouagadougou 03, Ouagadougou, Burkina Faso.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis B virus (HBV) infection, which can progress to liver cancer and even death, remains a public health problem. The high variability of HBV leading to the accumulation of mutations influences the natural history of this infection. Mutations in the precore/core region, in particular the G1896A mutation, have been associated with severe forms of liver disease in certain populations around the world. The aim of this study was to determine the molecular epidemiology of the HBV precore G1896A mutation and its relationship to hepatic complications in HBV chronically infected patients.

methodsClassical nested PCR was used to amplify the HBV precore region. A total of 97 samples consisting of 53 cases of chronic hepatitis B (CHB), 18 cases of hepatic cirrhosis (HC) and 26 cases of hepatocellular carcinoma (HCC) were amplified. The G1896A mutation was determined by enzymatic digestion on 81 samples using the restriction enzyme Bsu36I. Serological (HBeAg, anti-HBe Ac), biochemical (ALT) and virological (HBV-DNA viral load) tests were performed.

resultsThe frequency of the G1896A mutation was 44.44% in our study population. It was 56.82% in CHB cases, 28.57% in HC cases and 30.43% in HCC. The G1896A mutation was found more in subjects with a negative HBeAg status than in those with a positive HBeAg (p = 0.05) in the CHB subgroup. The DNA level was higher in subjects carrying wild-type strains for the G1896A mutation (p > 0.05). ALT levels were lower in subjects carrying the G1896A mutation than in those infected with wild-type strains (p = 0.006) in the HBC subgroup.

conclusionThis study, conducted on patients with chronic hepatitis B, cirrhosis, and hepatocellular carcinoma (HCC), showed that the frequency of the precore G1896A mutation was 44.44%. We found no correlation between this mutation and cirrhosis and HCC. However, it was more found in subjects with chronic hepatitis B and was associated with HBeAg negativity in the latter. It would therefore be involved in the elimination of this protein partly responsible for the persistence of HBV infection and could be a molecular marker for clinicians in the management of patients infected with HBV with negative HBeAg and positive anti-HBe antibodies. However, studies on other mutations of the precore gene would be necessary to obtain more conclusive results in terms of effective treatment.

Indexed as

Carcinoma, HepatocellularHepatitis B, ChronicHepatitis B virusLiver CirrhosisLiver NeoplasmsAdultBurkina FasoDNA, ViralFemaleHepatitis B e AntigensHumansMaleMiddle AgedMutationViral LoadDNA, ViralHepatitis B e AntigensBurkina FasoG1896A mutationHBeAg negativePrecore/coreViral hepatitis B

Identifiers

PMID40493277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.